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Abstract
This study aimed to evaluate the association between thyroid dysfunction and breast 
cancer risk. We included 239,436 females of the UK Biobank cohort. Information 
on thyroid dysfunction, personal and family medical history, medications, reproduc-
tive factors, lifestyle, and socioeconomic characteristics was retrieved from baseline 
self- reported data and hospital inpatient databases. Breast cancer diagnoses were 
identified through population- based registries. We computed Cox models to estimate 
hazard ratios (HRs) of breast cancer incidence for thyroid dysfunction diagnosis and 
treatments, and examined potential confounding and effect modification by comor-
bidities and breast cancer risk factors. In our study, 3,227 (1.3%) and 20,762 (8.7%) 
women had hyper- and hypothyroidism prior to the baseline. During a median fol-
low- up of 7.1 years, 5,326 (2.2%) women developed breast cancer. Compared to no 
thyroid dysfunction, there was no association between hypothyroidism and breast 
cancer risk overall (HR = 0.93, 95% confidence interval (CI): 0.84– 1.02, 442 cases), 
but we found a decreased risk more than 10 years after hypothyroidism diagnosis 
(HR=0.85, 95%CI 0.74– 0.97, 226 cases). There was no association with hyperthy-
roidism overall (HR=1.08, 95%CI 0.86– 1.35, 79 cases) but breast cancer risk was 
elevated among women with treated hyperthyroidism (HR=1.38, 95%CI: 1.03– 1.86, 
44 cases) or aged 60 years or more at hyperthyroidism diagnosis (HR=1.74, 95%CI: 
1.01– 3.00, 113 cases), and 5– 10 years after hyperthyroidism diagnosis (HR=1.58, 
95%CI: 1.06– 2.33, 25 cases). In conclusion, breast cancer risk was reduced long after 
hypothyroidism diagnosis, but increased among women with treated hyperthyroid-
ism. Future studies are needed to determine whether the higher breast cancer risk 
observed among treated hyperthyroidism could be explained by hyperthyroidism se-
verity, type of treatment or aetiology.
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1 |  INTRODUCTION
Breast cancer is the most frequent female neoplasm, with 
522,500 new cases diagnosed in Europe in 2018.1 It has a peak 
incidence at the age of 50– 70 years– – a feature shared by thy-
roid dysfunction, one of the most common endocrine disorders 
in females. Experimental data showed that thyroxine (T4) and 
triiodothyronine (T3) have proliferative and anti- apoptotic 
effects on breast cancer tumour cells by regulating gene ex-
pression and stimulating oestrogen- like effects,2,3 indicating an 
association between thyroid dysfunction and breast cancer risk.
However, epidemiological studies have provided inconsistent 
findings.4 Several studies reported higher blood levels of thyroid 
stimulating hormone (TSH), a biomarker of hypothyroidism, to 
be associated with a reduced breast cancer risk,5,6 while others 
reported no association.7– 9 In a meta- analysis of observational 
studies published up to 2019, no statistically significant associa-
tion between hypothyroidism and breast cancer risk was found,4 
but two more recent studies reported a reduced breast cancer 
risk associated with hypothyroidism.5,10 Conversely, some stud-
ies,11– 14 but not all,8,10 showed a higher breast cancer risk among 
hyperthyroid women compared to those without thyroid dys-
function, which was supported by results from the meta- analysis 
4 and a Mendelian randomization study.5 This could be, at least 
partly, due to hyperthyroidism treatments, since radioactive io-
dine (RAI) therapy has been associated with an increased breast 
cancer risk,13,15 but few studies had this information.
In this study, we aimed to estimate the association between 
hyper- and hypothyroidism (from self- report and medical re-
cords) and breast cancer risk among pre- and postmenopausal 
women, and investigated possible confounding or modifying 
effects of thyroid dysfunction treatment, comorbidities, and 
breast cancer risk factors, using data from the 2006– 2010 
cohort of the population- based UK Biobank (UKB) cohort.
2 |  MATERIALS AND METHODS
2.1 | Study population and data sources
From 2006 to 2010, the UKB cohort enrolled 273,375 
women from the general population. Participants were vol-
unteers aged from 39 to 71 years, and residing in England, 
Wales, or Scotland, who gave their written informed con-
sents.16 Detailed information on personal and family medi-
cal history, medications, reproductive and lifestyle factors, 
and socioeconomic and demographic characteristics was 
collected through a self- reported questionnaire, an interview 
with a trained nurse, and physical measurements at baseline. 
The cohort was linked to regional, population- based regis-
tries to collect hospital inpatient diagnostics and procedures 
(data availability starting between 1981 and 1998 depend-
ing on the region), cancer registration (since 1957 to 1971 
depending on the region), and death registration data (since 
2006). Since the registries did not cover the participants’ 
lives earlier than their availability date, we used those data 
sources for follow- up purposes, and both self- reported and 
registry- based data for baseline information (e.g. pre- existing 
cancer at baseline).
We included participants without cancer diagnosis of 
any type (except non- melanoma skin cancer) that was self- 
reported or recorded in cancer registries prior to baseline, 
i.e. the first visit at a UKB centre for study enrollment. We 
excluded women who underwent a mastectomy prior to base-
line, or had less than one year of follow- up. After exclusions, 
our study population included 239,436 women (Figure  1). 
Follow- up time started at baseline and ended at the date of 
any cancer diagnosis (except non- melanoma skin cancer), 
mastectomy, death, lost- to- follow- up, or 31 March 2016, 
whichever occurred first.
F I G U R E  1  Flowchart of the study 
population. * Women with both hyper- 
and hypothyroidism reported/recorded 
(n = 2,004) contributed to both columns of 
hyper- and hypothyroidism
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2.2 | Exposure
In the primary analyses, we used information on baseline 
thyroid dysfunction diagnosis (hyperthyroidism, hypothy-
roidism, no thyroid dysfunction reported/recorded) and 
treatments [hyperthyroidism: antithyroid drugs (ATDs) (car-
bimazole, propylthiouracil), RAI, thyroidectomy; hypothy-
roidism: thyroid hormones (liothyronine, thyroxine)] that 
was self- reported during the baseline interview or recorded 
(at least once) in a hospital inpatient database prior to base-
line (Table 1, Appendix 1). Hyperthyroidism and hypothy-
roidism were assessed separately.
We investigated the following exposure variables: ever di-
agnosis of hyper- /hypothyroidism, thyroid dysfunction treat-
ment modalities, time since diagnosis, time since treatment 
onset, age at diagnosis and calendar year of diagnosis.
2.3 | Outcome
Breast cancer cases were defined as diagnoses of invasive 
(n=4,452) or in situ cancers (n=874) recorded in the can-
cer registries (ICD- 10: C50 or D05, ICD- 9: 174 or 2330). 
We considered only first cancer occurrences. Women diag-
nosed with cancer of any type during follow- up (except non- 
melanoma skin cancer) were censored on diagnosis date.
2.4 | Potential confounders or 
effect modifiers
We considered comorbidities and breast cancer risk factors, 
and healthcare- related factors at baseline as potential con-
founders or effect modifiers (Appendix 2).
The comorbidities of interest were overweight/obesity, 
hypertension, diabetes, depression, and autoimmune condi-
tions. Type 1 and 2 diabetes were identified using a mod-
ified version of a published algorithm that was developed 
using the UKB data and validated against external primary 
and secondary care databases (Appendix 3).17 Since thyroid 
dysfunction aetiology was not systematically recorded in the 
UKB and various autoimmune conditions can occur among 
patients with thyroid autoimmune diseases such as Graves’ or 
Hashimoto's disease,18 we investigated a potential modifying 
effect by autoimmune conditions as a proxy for the autoim-
mune aetiology of thyroid dysfunction. We used a variable 
including any autoimmune condition other than autoimmune 
thyroid diseases at baseline (Appendix 4).19– 21
We considered well- established breast cancer risk factors 
as potential confounders or effect modifiers: menopausal sta-
tus, age at menarche, parity, age at first birth, family history 
of breast cancer, use of menopausal hormone therapy (MHT), 
use of oral contraception, and level of physical activities. 
Baseline age at menopause was defined as age at bilateral 
T A B L E  1  Sources of information and coding used to define thyroid dysfunction diagnosis and treatments
Self- reported data at baseline
Hospital inpatient databases





Regular use of propilthiouracil 
or carbimazole at baseline
242 E05 988 X655
Hypothyroidism Hypothyroidism
Regular use of liothyronine or 
thyroxine at baseline






Radioactive iodinea Thyroid radioablation therapy NA NA 988 X655
Surgerya,b Thyroidectomy NA NA 070, 071, 072 B08
Antithyroid drugs 
onlyc 
Regular use of propilthiouracil 




Thyroid hormones Regular use of liothyronine or 
thyroxine at baseline
NA NA
Abbreviations: ICD, International classification of diseases; NA, not applicableOPCS, OPCS Classification of Interventions and Procedures.
aOnly the first definitive hyperthyroidism treatment was considered, e.g. if radioactive iodine occurred before surgery, the treatment modality was coded as 
“radioactive iodine”.
bOnly procedures performed after a diagnosis of hyperthyroidism were considered.
cIf patients were treated with both antithyroid drugs and radioactive iodine/surgery, the treatment modality was coded as “radioactive iodine” or”surgery”, whichever 
occurred first.
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oophorectomy or reported menopause whichever occurred 
first. If unknown, it was defined in order of priority as age 
at MHT initiation, or 51 years otherwise. The age threshold 
corresponds to the median value of age at menopause in the 
study population.
Other factors suggested to be possibly associated with 
breast cancer risk in the literature were considered as poten-
tial confounders: race, alcohol consumption, and smoking 
status. Townsend deprivation score of residence, educational 
attainment, occupation, and adherence to breast and cervical 
cancer screening programs, which might reflect different lev-
els of health care access and cancer surveillance, were also 
analysed as potential confounders.
For all the above- mentioned factors, missing data were in-
frequent (<5%, except age at menopause: 9.3%), and handled 
either by defining an “unknown” category (for categorical 
variables) or imputing the median value in the study popula-
tion (for continuous variables).
2.5 | Statistical analyses
We used Cox proportional hazards models to compute haz-
ards ratios (HRs) and 95% confidence intervals (CIs) of breast 
cancer incidence according to thyroid dysfunction diagnosis 
and treatments. Time since baseline (i.e. UKB inclusion) was 
considered as the time scale. Models were adjusted for age at 
baseline, menopausal status, family history of breast cancer, 
parity and age at first birth, and level of physical activity. 
Proportional hazards assumptions were graphically evalu-
ated based on plots of scaled Schoenfeld residuals against 
time, and tested by introducing an interaction term between 
thyroid dysfunction and follow- up time. No evidence of non- 
proportionality was found.
Potential confounding effect was assessed by evaluating 
the age- adjusted associations with thyroid dysfunction, and 
changes in adjusted HRs for breast cancer risk exceeding 
10%.22 Effect modification was evaluated by testing the sta-
tistical significance of an interaction term between thyroid 
dysfunction and the studied covariate [likelihood- ratio χ² 
tests for heterogeneity (categorical variables) and linear trend 
(continuous variables)]. When statistically significant multi-
plicative interactions were detected, we reported results for 
both additive and multiplicative interactions.23
Several sensitivity analyses were conducted. While hyper-
thyroid patients are usually treated, the proportion of hyper-
thyroid women without information on treatment was too high 
to be considered as untreated individuals. Since ATDs are 
used as the first- line treatment for Graves’ disease (the most 
common cause of hyperthyroidism) in the UK 24,25 and was 
more likely to be missed when retrieving information com-
pared to surgery and RAI in the UKB, we hypothesized that 
women with no information on treatments were treated with 
ATDs, and conducted sensitivity analyses while combining 
them and women treated with ATDs. Thyroidectomy can be 
used to treat other thyroid diseases and thyroid dysfunction 
could be a transient condition before other thyroid disorders, 
therefore, we excluded women with other baseline thyroid 
problems, e.g. thyroiditis, and non- toxic goitre. To minimize 
misclassification, we conducted an analysis stratified by the 
order of thyroid dysfunction occurrence and excluded women 
who had hypothyroidism reported/recorded before hyperthy-
roidism or who had hyper- and hypothyroidism reported/
recorded with unknown sequential order of occurrence. We 
also analysed separately thyroid dysfunction diagnoses and 
treatments recorded in the hospital databases only (likely re-
flecting the most severe conditions), and self- reported data 
only to assess the impact of the data sources on the results. 
We added information on new thyroid dysfunction diagnoses 
and hyperthyroidism treatment identified in the hospital da-
tabases during follow- up, by considering exposure as a time- 
dependent variable. We evaluated the association between 
thyroid dysfunction and invasive breast cancer risk only. We 
also computed cause- specific hazard models 26 to consider 
death and non- breast cancer incidence as competing risks. 
Lastly, we did a sensitivity analysis by excluding women with 
missing data in covariates.
3 |  RESULTS
3.1 | Population description
The prevalence of hyper- and hypothyroidism at baseline was 
1.3% and 8.7%, respectively. Compared to women with no 
thyroid dysfunction, hyper- and hypothyroid women were 
likely to be older, postmenopausal, MHT and oral contracep-
tion ever user, obese/overweight, to have had a child at an 
earlier age, to have a lower level of physical activity, and 
more comorbidities at baseline (Table 2, Table S1). During 
a median follow- up time of 7.1 years, 5326 (2.2%) women 
were diagnosed with breast cancer.
3.2 | Hyperthyroidism
We found no statistically significant association between 
breast cancer risk and hyperthyroidism in overall (Table 3), 
but an increased risk at 5– 10  years after hyperthyroidism 
diagnosis (HR=2.38, 95% CI 1.19– 4.76), among women 
who were diagnosed with hyperthyroidism after the age of 
60 years (HR=1.74, 95% CI 1.01– 3.00), or among women 
who were treated for hyperthyroidism (HR=1.38, 95% CI 
1.03– 1.86). Stratification by treatment status showed that 
the increase of risk among women who were diagnosed with 
hyperthyroidism for 5– 10 years or at the age of 60 years or 
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p- valueb p - valueb 
Person- years of follow- up, median (IQR) 7.1 (6.4, 7.8) 7.1 (6.4, 7.8) 0.377 7.0 (6.4, 7.8) < 0.001
Age at baseline, Mean (SD) 56.4 ± 8.1 58.0 ± 7.6 <0.001 58.9 ± 7.3 <0.001
Menopause status, n (%) <0.001 <0.001
Still had periods 60,047 (27.6) 612 (19.0) 3,189 (15.4)
Had menopause before the age of 51 106,860 (49.1) 1,764 (54.7) 12,105 (58.3)
Had menopause after the age of 51 50,544 (23.2) 851 (26.4) 5,468 (26.3)
Age at menopausec , Mean (SD) 49.3 ± 5.1 49.2 ± 5.4 0.918 49.0 ± 5.5 < 0.001
Age at menarche, Mean (SD) 13.0 ± 1.6 12.9 ± 1.6 0.213 12.9 ± 1.6 <0.001
Family history of breast cancer, n (%) 22,951 (10.6) 309 (9.6) 0.077 2,113 (10.2) 0.093
Ever use of menopausal hormone therapyc , n (%) <0.001 <0.001
No 77,660 (49.3) 1,193 (45.6) 7,473 (42.5)
Yes, for less than 5 years 27,624 (17.5) 442 (16.9) 3,206 (18.2)
Yes, for more than 5 years 41,604 (26.4) 764 (29.2) 5,384 (30.6)
Yes, unknown duration 9,723 (6.2) 206 (7.9) 1,432 (8.1)
Unknown 793 (0.5) 10 (0.4) 78 (0.4)
Ever use of oral contraception, n (%) <0.001 <0.001
No 39,784 (18.3) 723 (22.4) 4,722 (22.7)
Yes, for less than 10 years 78,956 (36.3) 1,216 (37.7) 7,855 (37.8)
Yes, for more than 10 years 78,019 (35.9) 972 (30.1) 6,070 (29.2)
Yes, unknown duration 20,338 (9.4) 308 (9.5) 2,078 (10.0)
Unknown 354 (0.2) 8 (0.2) 37 (0.2)
Parity and age at first birth, n (%) <0.001 <0.001
No live birth 41,026 (18.9) 567 (17.6) 3,336 (16.1)
≥ one child, <30 years old at birth 135,291 (62.2) 2,134 (66.1) 14,340 (69.1)
≥ one child, ≥30 years old at birth 40,071 (18.4) 516 (16.0) 3,007 (14.5)
Unknown 1,063 (0.5) 10 (0.3) 79 (0.4)
Corpulence, n (%) 0.024 <0.001
Obesity/Overweight, BMI ≥25 kg/m² 128,257 (59.0) 1,974 (61.2) 14,564 (70.1)
Normal weight/Underweight, BMI <25 kg/m2 88,047 (40.5) 1,239 (38.4) 6,107 (29.4)
Unknown 1,147 (0.5) 14 (0.4) 91 (0.4)
Comorbidities, n (%) <0.001 <0.001
Type 2 diabetes 6,534 (3.0) 166 (5.1) 1,203 (5.8)
Hypertension 49,848 (22.9) 1,006 (31.2) 6,579 (31.7)
Depression 15,145 (7.0) 263 (8.1) 2,027 (9.8)
Autoimmune diseases 20,263 (9.3) 450 (13.9) 2,851 (13.7)
Levels of physical activities, n (%) 0.002 <0.001
Low 68,804 (31.6) 1,106 (34.3) 7,438 (35.8)
Moderate 77,862 (35.8) 1,146 (35.5) 7,084 (34.1)
High 70,785 (32.6) 975 (30.2) 6,240 (30.1)
Abbreviation: BMI, Body- mass index
aWomen with both hyper- and hypothyroidism reported/recorded (n=2,004) contributed to both columns of hyper- and hypothyroidism.
bp- value of t- test, Mann- Whitney U test and χ2 test, where appropriate.
cPostmenopausal women only.
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No. of breast 
cancer cases/
Person- years HR 95%CI
No. of breast 
cancer cases/
Person- years HR 95%CI
No thyroid dysfunction 
(reference)
4,854/1,518,670 1 — 4,854/1,518,670 1 — 
Overall 79/22,520.6 1.08 0.86, 1.35 442/144,213.1 0.93 0.84, 1.02
Age at diagnosis
Before 40 years old 20/8,436.4 0.75 0.48, 1.16 50/23,615.7 0.71 0.54, 0.94
Between 40– 60 years old 45/11,725 1.18 0.88, 1.58 271/87,945.4 0.94 0.83, 1.06
After 60 years old 13/2,007.2 1.74 1.01, 3.00 70/16,728.3 1.11 0.88, 1.41
Unknown age at diagnosis 1/352 0.92 0.13, 6.56 51/15,923.6 0.97 0.73, 1.27
P- trenda 0.145 0.452
Time since diagnosis
Less than 5 years ago 4/2,333.6 0.70 0.26, 1.87 34/15,154.9 0.91 0.65, 1.27
Between 5– 10 years ago 25/4,947.4 1.58 1.06, 2.33 131/37,024.4 1.08 0.91, 1.29
More than 10 years ago 49/14,887.6 0.97 0.73, 1.29 226/76,110.1 0.85 0.74, 0.97
Unknown time at diagnosis 1/352 0.91 0.13, 6.47 51/15,923.6 0.99 0.75, 1.30
P- trenda 0.124 0.872
Calendar year at diagnosis
Before 1990 26/6,910.3 1.09 0.74, 1.61 47/17,558.6 0.79 0.59, 1.05
1990– 2000 14/5,946.9 0.74 0.44, 1.24 120/40,954.8 0.88 0.73, 1.05
After 2000 38/9,317.3 1.29 0.94, 1.77 224/69,814.3 0.99 0.86, 1.13
Unknown time at diagnosis 1/346.2 0.93 0.13, 6.60 51/15,885.4 0.96 0.73, 1.27
P- trenda 0.366 0.352
Treatment status
Without information on treatment 
(1)
35/12,816.1 0.84 0.60, 1.17 22/4,831.6 1.39 0.91, 2.11
With information on treatment 44/9,704.5 1.38 1.03, 1.86 420/139,381.5 0.91 0.83, 1.01
Types of hyperthyroidism treatment
Antithyroid medications (2) 9/1,978 1.46 0.76, 2.81
RAI (3) 11/2,697.4 1.23 0.68, 2.23
Surgery (4) 24/5,029.1 1.44 0.96, 2.15
(1) or (2) 44/14,794.1 0.92 0.68, 1.24
(3) or (4) 35/19,822.2 1.37 0.98,1.91
Time since hyperthyroidism treatment
Less than 5 years ago 1/435.2 0.97 0.14, 6.90
Between 5– 10 years ago 8/1,068.6 2.38 1.19, 4.76
More than 10 years ago 26/6,192.9 1.24 0.84, 1.82
Unknown time at diagnosis 9/2,007.8 1.43 0.74, 2.74
P- trenda 0.044
Note: HRs are adjusted for age at baseline (continuous), family history of breast cancer (yes/no), parity and number of live birth (No live birth/≥ one child, <30 years 
old at birth/≥ one child, ≥30 years old at birth/Unknown), menopausal status (premenopause/postmenopause before the age of 51/postmenopause after the age of 51), 
physical activities (Low/Moderate/High).
Abbreviations: HR, Hazard Ratio, CI, Confidence Interval, RAI, Radioactive iodine therapy.
ap- trend was calculated after excluding hyperthyroidism/hypothyroidism with unknown time at diagnosis/treatment.
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more, only concerned treated individuals, while there was no 
association among women with no information on treatment 
(Table A3). The results did not substantially differ in sensi-
tivity analyses (Tables S4, S6, Figure S1).
For treated hyperthyroidism, there was a higher breast 
cancer risk among women menopaused at ages >51  years 
(HR=2.07, 95% CI 1.33– 3.22) compared to women who had 
earlier menopause (HR=1.18, 95% CI 0.76– 1.83) or were 
premenopausal at baseline (HR=0.79, 95% CI 0.30– 2.11) 
(p- heterogeneity=0.09) (Table  4). We found no confound-
ing or modifying effect by comorbidities, and breast cancer 
risk factors, except hypertension based on very few cases 
(Figure S2).
3.3 | Hypothyroidism
We found no statistically significant association between hy-
pothyroidism and breast cancer risk, overall (HR=0.93, 95% 
CI 0.84– 1.02), or after stratification by calendar year at di-
agnosis or treatment (Table 3). However, there was a lower 
risk among women diagnosed with hypothyroidism before 
the age of 40 years (HR=0.71, 95% CI 0.54– 0.94) or diag-
nosed for hypothyroidism for more than 10 years (HR=0.85, 
95% CI 0.74– 0.97). The results did not substantially differ in 
sensitivity analyses (Tables S5, S6 , Figure S1).
We found no confounding or modifying effect by comor-
bidities, and breast cancer risk factors (Figure  S2), except 
age at menopause. We observed lower risks among pre-
menopausal women at baseline (HR=0.69, 95% CI 0.51– 
0.93) or women menopaused at ages ≤ 51 years (HR=0.90, 
95% CI 0.79– 1.02) compared to those with later menopause 
(HR=1.10, 95% CI 0.93– 1.30) (p- value for heterogeneity: 
0.017) (Table 5). The results of analyses on age at menopause 
did not vary after adjustment for age at menopause (for post-
menopausal women) and in further analyses stratified by age 
at baseline, natural or artificial menopause, age at or time 
since hypothyroidism diagnosis, occurrence of thyroid dys-
function before or after menopause, or use of MHT or not.
4 |  DISCUSSION
In this study, there was no association between thyroid dys-
function and breast cancer risk overall. However, breast can-
cer risk varied according to hyperthyroidism treatment status, 
with a 38% higher breast cancer risk in women treated for 
hyperthyroidism compared to women with no thyroid dys-
function and no increased risk among hyperthyroid women 
without information on treatment. The risk was particularly 
elevated at 5– 10 years after hyperthyroidism diagnosis and 
among women diagnosed for hyperthyroidism at the age of 
60 years or more. Women with a history of hypothyroidism 
for 10 years or more or diagnosed before the age of 40 years 
were at a lower risk of breast cancer. Menopausal status and 
age at menopause modified the association of both treated 
hyper- and hypothyroidism.
Accumulated evidence in recent years has not provided a 
clear understanding of the role of hypothyroidism on breast 
cancer risk. Some 5,6,10 but not all studies 7- 9 have suggested 
that higher blood levels of TSH and thyroid hormone re-
placement therapy were associated with a reduced risk of 
breast cancer. Our findings showed an inverse association be-
tween breast cancer risk and hypothyroidism among women 
T A B L E  4  Breast cancer risk associated with treated hyperthyroidism according to baseline menopausal status and age at menopause
Menopausal status and age at 
menopause
N with/without breast 
cancer HR (95% CI)
HR (95% CI) within strata of 
menopausal status and age at menopause
Premenopause
No thyroid dysfunction 1,194/58,853 1.19 (1.07– 1.31), p = 0.001 1.00
Treated hyperthyroidism 4/248 0.91 (0.34– 2.44), p = 0.856 0.77 (0.29– 2.05), p = 0.601
Having menopause before the age of 51
No thyroid dysfunction 2,341/104,519 1.00 1.00
Treated hyperthyroidism 20/743 1.19 (0.76– 1.84), p = 0.443 1.19 (0.76– 1.84), p = 0.443
Having menopause after the age of 51
No thyroid dysfunction 1,319/49,225 1.16 (1.08– 1.24), p < 0.001 1.00
Treated hyperthyroidism 20/358 2.39 (1.54– 3.71), p < 0.001 2.07 (1.33– 3.22), p = 0.001
Note: Measure of effect modification of premenopause on additive scale: Treated hyperthyroidism: RERI (95% CI)  = −0.46 (−1.5– 0.58), p  =  0.391. Measure of 
effect modification of having menopause after the age of 51 on additive scale: Treated hyperthyroidism: RERI (95% CI)  = 1.05 (−0.12– 2.22), p  =  0.08. Measure 
of effect modification of premenopause on multiplicative scale: Treated hyperthyroidism: ratio of HRs (95% CI)  = 0.65 (0.22– 1.9), p  =  0.429. Measure of effect 
modification of having menopause after the age of 51 on multiplicative scale: Treated hyperthyroidism: ratio of HRs (95% CI)  = 1.74 (0.93– 3.25), p  =  0.081. HRs are 
adjusted for age at baseline (continuous), family history of breast cancer (yes/no), parity and number of live birth (No live birth/≥ one child, <30 years old at birth/≥ 
one child, ≥30 years old at birth/Unknown), and physical activities (Low/Moderate/High).
   | 4611TRAN eT Al.
diagnosed before 40 years of age or only after 10 years of 
hypothyroidism, in partial agreement with a previous meta- 
analysis and a recent study.4,10
In the current study, we reported an increased risk of 
breast cancer among women with treated hyperthyroidism 
while the meta- analysis 4 and two nationwide hospital cohort 
studies 11,12 suggested a higher risk with hyperthyroidism 
in general. Of note, in those studies, hyperthyroidism was 
mainly ascertained through hospital databases, thus, probably 
mostly including treated cases. One of the cohort studies 11 
also had an older population compared to ours, which might 
partly explain the overall elevated risk with hyperthyroidism. 
In contrast, a recent cohort study did not find any associa-
tion between self- reported hyperthyroidism and breast cancer 
risk, but information on treatment was limited and only avail-
able for medications.10
In our study, baseline characteristics did not differ sub-
stantially between hyperthyroidism with/without information 
on treatment (Table S2). Increased risk among hyperthyroid 
women with information on treatments, but not among those 
without information might be explained by surveillance bias, 
types of treatment themselves, or treatment- related factors. 
Women with treated hyperthyroidism could possibly have 
more regular health care consultations. However, the in-
creased risk remained after 10  years of diagnosis and did 
not change after accounting for health care- related factors. 
Thus, surveillance bias was unlikely to be a major explana-
tory factor. Besides, hyperthyroid patients treated with RAI 
have been suggested to have a higher breast cancer risk, in re-
lation to the radiation dose received. However, as the possible 
effect of RAI is modest and observed only after a long la-
tency period,13,15 it was unlikely the principal cause of the 
higher breast cancer risk among treated hyperthyroidism in 
our study. Moreover, we found consistent risks across differ-
ent types of treatment, suggesting that breast cancer risk in 
treated hyperthyroidism was unlikely attributable solely to a 
specific treatment type.
Treatments are generally not recommended in subclinical 
hyperthyroidism when overt conditions are often treated as 
soon as diagnosed.27 In the current study, hyperthyroid pa-
tients without information on treatment could have subclini-
cal hyperthyroidism, which can be endogenous or exogenous 
(due to overtreated hypothyroidism), while patients with in-
formation on treatment might suffer from overt conditions. A 
recent large population- based linked- record study in the UK 
found that the majority (74%) of patients with Graves’ disease 
were treated with ATDs.25 Since the recommended length of 
an ATDs course often lasts no longer than 12– 18 months, and 
in the UKB cohort, only ATDs which were regularly being 
taken at baseline were recorded, and not before, it is possible 
that hyperthyroid women without information on treatment 
were actually treated with ATDs, and we found no association 
with breast cancer risk among these patients in the sensitivity 
analysis including all those subjects as treated with ATDs. 
Nevertheless, we always observed higher breast cancer risks 
among hyperthyroidism treated with definitive treatments 
(RAI, surgery), which are preferred among patients with re-
current hyperthyroidism (likely having more severe manifes-
tation 28) or hyperthyroidism caused by toxic nodular goiter. 
Previous studies have suggested that the higher breast cancer 
T A B L E  5  Breast cancer risk associated with hypothyroidism according to baseline menopausal status and age at menopause
Menopausal status and age at 
menopause
N with/without breast 
cancer HR (95% CI)
HR (95% CI) within strata of 
menopausal status and age at 
menopause
Premenopause
No thyroid dysfunction 1194/58853 1.19 (1.08– 1.32), p = 0.001 1.00
Hypothyroidism 44/3145 0.82 (0.61– 1.12), p = 0.214 0.69 (0.51– 0.93), p = 0.016
Having menopause before the age 
of 51
No thyroid dysfunction 2341/104519 1.00 1.00
Hypothyroidism 240/11865 0.90 (0.79– 1.02), p = 0.109 0.90 (0.79– 1.02), p = 0.109
Having menopause after the age 
of 51
No thyroid dysfunction 1319/49225 1.15 (1.08– 1.24), p < 0.001 1.00
Hypothyroidism 158/5310 1.27 (1.08– 1.49), p = 0.004 1.10 (0.93– 1.30), p = 0.261
Note: Measure of effect modification of premenopause on additive scale: Hypothyroidism: RERI (95% CI)  = −0.26 (−0.55– 0.02), p  =  0.066. Measure of effect 
modification of having menopause after the age of 51 on additive scale: Hypothyroidism: RERI (95% CI)  = 0.22 (−0.02– 0.46), p  =  0.073. Measure of effect 
modification of premenopause on multiplicative scale: Hypothyroidism: ratio of HRs (95% CI)  = 0.77 (0.55– 1.07), p  =  0.121. Measure of effect modification of 
having menopause after the age of 51 on multiplicative scale: Hypothyroidism: ratio of HRs (95% CI)  = 1.23 (0.99– 1.51), p  =  0.06. HRs are adjusted for age at 
baseline (continuous), family history of breast cancer (yes/no), parity and number of live birth (No live birth/≥ one child, <30 years old at birth/≥ one child, ≥30 years 
old at birth/Unknown), and physical activities (Low/Moderate/High).
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risk associated with hyperthyroidism was strongest among 
patients with toxic nodular goiters.12,29 In our study, breast 
cancer risk did not vary when stratifying by the presence of 
autoimmune disease. Thus, the aetiology of thyroid dysfunc-
tion might not be related to the increased risk.
Most,6,7,9,30 but not all,8 previous studies found breast can-
cer risk increased with increasing blood levels of thyroxine 
(a marker of hyperthyroidism severity). A recent study which 
included women without thyroid medication found that both 
abnormal high blood levels of thyroxine and thyroxine in the 
euthyroid range were associated with higher breast cancer 
risk, but the risk associated with overt hyperthyroidism was 
higher than that with subclinical conditions.6
Biological mechanisms underlying the association be-
tween breast cancer risk and TSH remains unclear, but a num-
ber of explanation for thyroid hormones have been explored 
in vitro and in vivo. T4 and T3 activate MPAK pathways and 
phosphorylate ER α, inducing cell proliferation.2,3,31 T3 can 
also enhance the effect of oestrogens on breast cell prolif-
eration,32 and directly increases aerobic glycolysis, a hall-
mark of cancer, which is known as Warburg effect.2 T4 is 
known to have anti- apoptotic properties, which act via the 
integrin α vβ3, by stimulating gene expression of cancer cell 
defense.33,34 Moreover, excessive or insufficient iodine in-
take, which plays a key role in thyroid hormone production, 
could also be a risk factor for breast cancer.35 Taken together, 
current experimental evidence supports a positive association 
between high levels of thyroid hormones and a higher risk of 
breast cancer.
In this study, the breast cancer risk estimates for thyroid 
dysfunction were not affected by a wide range of potential 
confounders and effect modifiers, except menopausal status 
and late age at menopause irrespective of other factors. Few 
studies have investigated a potential effect modification by 
menopausal status and reproductive factors. A recent study 
showed a positive association between hyperthyroidism and 
reproductive risk factors of breast cancer.12 In a large cohort 
of postmenopausal women, the reduced risk of breast cancer 
associated with hypothyroidism disappeared among women 
who used MHT for any duration.10 Some other studies found 
evidence of a stronger association with high levels of T4 
among postmenopausal women compared to premenopausal 
ones.6,7,30 Among postmenopausal women, the association 
between T4 and breast cancer risk was also stronger among 
obese women,30 who had higher oestrogen blood concen-
tration than women with normal weight.36 Taken together, 
the current evidence suggested that reproductive factors 
might modify the breast cancer risk associated with thyroid 
dysfunction.
Late age at menopause has been confirmed risk factor 
of breast cancer, which lengthens the cumulative exposure 
to cycling reproductive hormones among women.37 After 
menopause, endogenous oestrogen is produced dominantly 
by the peripheral conversion of androgens in adipose tissue,36 
which is represented by BMI. Almost 40%– 50% variation in 
natural age at menopause has been suggested to be attribut-
able to genetic factors.38,39 However, in our study, the associ-
ation between breast cancer and thyroid dysfunction did not 
vary according to other genetic- and oestrogen- related fac-
tors. Besides, although the proportion of ER + and ER- breast 
cancer has been shown to vary according to age at breast can-
cer diagnosis among both pre- and postmenopausal women,37 
we observed no substantial difference in the distribution of 
age at breast cancer diagnosis according to thyroid dysfunc-
tion and menopausal status. Thus, the underlying biological 
mechanisms of the effect modification by menopausal status 
and age at menopause remain unclear.
The current study has major strengths, including a large 
population size, a high level of follow- up completeness and 
outcome ascertainment through regional registries and hos-
pital databases, and its wide range of available information. 
The crossover among inpatient data and self- reported data 
on personal medical history allowed us to capture a broad 
range of health conditions. The UKB also includes detailed 
information on reproductive factors, lifestyle, socioeconomic 
status and family medical history with low levels of missing 
data, which helped us to study essential risk factors.
However, several limitations can be flagged. Details on 
cancer stage, grade, and receptor status were unavailable, and 
we could not investigate whether the risk estimates varied 
according to tumour characteristics. Lack of information on 
laboratory measurements of thyroid hormones, aetiology, 
and clinical symptoms of thyroid dysfunction prevented us 
from determining the severity, the exposure window of thy-
roid dysfunction (as overt conditions are often treated as soon 
as diagnosed) and disentangling the independent role of se-
verity, and aetiology. We were unable to account for thyroid 
dysfunction diagnosis/treatments for the whole study popu-
lation during follow- up or to study the independent effects 
of thyroid dysfunction treatments, and evaluate the impact 
of different treatment- related factors: RAI dosage, partial 
versus total thyroidectomy, duration of use and adherence to 
ATDs prescription. In the hyperthyroidism analyses, given 
that the higher risks were consistent across different types 
of treatment, accounting for treatment- related factors is un-
likely to change our risk estimates. However, considering the 
intertwined relationship between hyperthyroidism aetiology, 
severity and treatment for further research is needed to con-
firm our finding. The data on comorbidities were also quite 
limited with no information on severity, age at onset, and du-
ration of conditions, so it is possible that we did not account 
for all the possible effects of comorbidities on the association 
between thyroid dysfunction and breast cancer risk.
In conclusion, our study suggested that higher breast 
cancer risk among hyperthyroid women could be explained 
by hyperthyroidism severity or aetiology, while there was a 
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lower risk among women with 10  years or more of hypo-
thyroidism. The association between thyroid dysfunction and 
breast cancer risk was modified by menopausal status and 
age at menopause, suggesting that the positive association be-
tween increased blood levels of thyroid hormones and breast 
cancer risk was even stronger with late age at menopause.
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